Podocalyxin in Normal Tissue and Epithelial Cancer

• Published in: Cancers Vol. 13; no. 12; p. 2863
• Main Authors: Le Tran, Ngoc, Wang, Yao, Nie, Guiying
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 08.06.2021; MDPI
• Subjects: Biomarkers; Brain; Cancer; CD34 antigen; Cell cycle; Cell surface; Chemoresistance; Chemotherapy; Clinical outcomes; Cytology; Endothelial cells; Epithelial cells; Epithelium; Hemopoiesis; Inflammation; Kidneys; Medical prognosis; Membrane proteins; Mesothelium; Metastases; Metastasis; Mutation; Permeability; Prognosis; Proteins; Review; Transcription factors; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13122863

Podocalyxin (PODXL), a glycosylated cell surface sialomucin of the CD34 family, is normally expressed in kidney podocytes, vascular endothelial cells, hematopoietic progenitors, mesothelium, as well as a subset of neurons. In the kidney, PODXL functions primarily as an antiadhesive molecule in podocyte epithelial cells, regulating adhesion and cell morphology, and playing an essential role in the development and function of the organ. Outside the kidney, PODXL plays subtle roles in tissue remodelling and development. Furthermore, many cancers, especially those that originated from the epithelium, have been reported to overexpress PODXL. Collective evidence suggests that PODXL overexpression is linked to poor prognosis, more aggressive tumour progression, unfavourable treatment outcomes, and possibly chemoresistance. This review summarises our current knowledge of PODXL in normal tissue function and epithelial cancer, with a particular focus on its underlying roles in cancer metastasis, likely involvement in chemoresistance, and potential use as a diagnostic and prognostic biomarker.